Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Multicenter Study of Patients With Arterial Hypertension and Chronic Kidney Disease Markers in Kazakhstan (PROGRESS-CKD)

NCT06744335 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06744335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06744335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Multicenter Study of Patients With Arterial Hypertension and Chronic Kidney Disease Markers in Kazakhstan (PROGRESS-CKD)
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
January 20, 2025
Completion date
August 20, 2026
Enrollment
1,283 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

demographic and clinical characteristics for those patients, rate of ckd diagnosis in patients with ah and ckd markers, routine therapy before and after the diagnosis of ckd